Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. Oncology Pharma will pursue the early feasibility and nonclinical development of a dactinomycin nanoemulsion drug product intended for the treatment of pediatric cancer.
加利福尼亚州旧金山/ACCESSWIRE/2021年8月19日/亚洲网加利福尼亚州米尔皮塔斯2月17日电肿瘤学制药公司(场外交易代码：ONPH)怀着万众期待，与NanoSmart制药公司敲定了一项共同开发协议。肿瘤学制药公司将致力于开发一种用于治疗儿童癌症的放线菌素纳米乳剂药物产品的早期可行性和非临床开发。
Oncology Pharma is pleased to be moving forward with the development of its first product based upon licensed technology in Oncology Pharma's growing portfolio of licensed intellectual property. Oncology Pharma's agreement with NanoSmart Pharmaceuticals will allow for continued development of a proprietary lead-candidate formulation leading to the submission of an Investigational New Drug application to the US FDA. This phase of cancer drug development is intended to also support potential applications in veterinary oncology.
肿瘤学制药公司很高兴在肿瘤学制药公司不断增加的特许知识产权组合中，以特许技术为基础开发其第一种产品。肿瘤学制药公司与NanoSmart制药公司达成的协议将允许继续开发一种专利候选配方，从而向美国食品和药物管理局提交一份研究用新药申请。这一阶段的抗癌药物开发也旨在支持兽医肿瘤学的潜在应用。
Oncology Pharma is excited to be combining efforts with NanoSmart Pharmaceuticals to pursue research and develop of improved treatments for pediatric cancers.
肿瘤学制药公司很高兴能与NanoSmart制药公司共同努力，研究和开发儿童癌症的改进治疗方法。
ABOUT ONCOLOGY PHARMA, INC.
肿瘤学制药公司简介
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
肿瘤学制药公司(Oncology Pharma，Inc.)OTCPK：ONPH)(“本公司”)目前正在从事肿瘤学疗法的研究和开发，并为拥有一个世界级的顾问委员会而感到自豪，该委员会使本公司在癌症研究、生物技术和医疗保健领域的技术开发处于领先地位。
ABOUT NANOSMART PHARMACEUTICALS, INC.
Nanosmart制药公司简介
NanoSmart® Pharmaceuticals is a privately-held California corporation that is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to target existing drug therapies to areas of necrosis present in virtually all solid cancer tumors.
Nanosmart®PharmPharmticals是一家私人持股的加州公司，正在开发纳米药物输送平台，包括利用抗核抗体(ANA)针对几乎所有实体癌症肿瘤中存在的坏死区域进行现有药物治疗。
FORWARD LOOKING STATEMENTS
前瞻性陈述
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships, and costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
本公告中讨论的某些事项包含前瞻性陈述，这些陈述涉及公司业务的重大风险和不确定性，可能导致实际结果与本文所作陈述预期的结果大不相同。这些风险和不确定因素包括与许可安排和合资企业有关的风险，包括需要就关系的最终协议进行谈判；可能无法实现商业关系的预期利益，以及为这些商业关系提供资金的成本。与本公司有关的其他风险和不确定因素包括：当前运营现金流为负，需要额外资金为我们的运营计划提供资金；任何进一步融资的条款，可能具有高度稀释作用，可能包括苛刻的条款；意想不到的成本和运营赤字，以及低于预期的销售和收入；客户采用新技术的意愿和能力不确定，以及其他可能影响进一步市场接受度的因素；不利的经济状况；任何法律诉讼的不利结果；我们的经营业绩和财务状况的波动；无法吸引或留住合格的高级管理人员，包括销售和市场营销。我们通过专利过程建立和维护我们技术的专有性质的能力, 以及我们可能从其他公司获得开发产品所需的专利和专利申请许可的能力；公司实施其技术各种应用的长期业务计划的能力；公司与任何必要的营销和/或分销合作伙伴以及与任何战略或合资伙伴签订协议的能力；竞争的影响；获得和保持适用于公司技术应用的任何必要的监管许可；增长管理；以及其他风险和不确定因素。这不是买卖证券的征集，也不是对公司财务状况的分析。
CONTACTS:
联系人：
For additional Information, please contact the Oncology Pharma at:
如需更多信息，请联系肿瘤学制药公司，网址为：
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
桑瑟姆街一号，套房3500加利福尼亚州旧金山，邮编：94104电话：415-869-1038传真：415-946-8801网址：www.oncology-pharma.com电子邮件：info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
资料来源：肿瘤学制药公司(Oncology Pharma Inc.)